DE69616749D1 - Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe - Google Patents

Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe

Info

Publication number
DE69616749D1
DE69616749D1 DE69616749T DE69616749T DE69616749D1 DE 69616749 D1 DE69616749 D1 DE 69616749D1 DE 69616749 T DE69616749 T DE 69616749T DE 69616749 T DE69616749 T DE 69616749T DE 69616749 D1 DE69616749 D1 DE 69616749D1
Authority
DE
Germany
Prior art keywords
flamming
agents
aryl substituted
nitro compounds
aromatic nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69616749T
Other languages
English (en)
Other versions
DE69616749T2 (de
Inventor
Yves Gauthier
K Lau
Yves Leblanc
Chun-Sing Li
Patrick Roy
Michel Therien
Zhaoyin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of DE69616749D1 publication Critical patent/DE69616749D1/de
Publication of DE69616749T2 publication Critical patent/DE69616749T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69616749T 1995-01-11 1996-01-10 Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe Expired - Fee Related DE69616749T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/371,179 US5552422A (en) 1995-01-11 1995-01-11 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
PCT/CA1996/000014 WO1996021667A1 (en) 1995-01-11 1996-01-10 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
DE69616749D1 true DE69616749D1 (de) 2001-12-13
DE69616749T2 DE69616749T2 (de) 2002-08-01

Family

ID=23462829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69616749T Expired - Fee Related DE69616749T2 (de) 1995-01-11 1996-01-10 Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe

Country Status (9)

Country Link
US (1) US5552422A (de)
EP (1) EP0802917B1 (de)
JP (1) JPH11501902A (de)
AT (1) ATE208397T1 (de)
AU (1) AU697650B2 (de)
CA (1) CA2209895A1 (de)
DE (1) DE69616749T2 (de)
ES (1) ES2165969T3 (de)
WO (1) WO1996021667A1 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419247A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4419315A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419246A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE69816651T2 (de) 1997-09-05 2004-04-01 Glaxo Group Ltd., Greenford 2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
FR2771005B1 (fr) * 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
PL348208A1 (en) * 1998-11-03 2002-05-06 Glaxo Group Ltd Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
DE10004157A1 (de) 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie
DK1255547T3 (da) 2000-02-08 2008-12-01 Euro Celtique Sa Kontrolleret-frigivelsessammensætninger indeholdende opioid-agonist og antagonist
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2001290243A1 (en) * 2000-09-20 2002-04-02 Nikken Chemicals Co., Ltd. Novel thiazole bicyclic compounds
JP2004518651A (ja) * 2000-12-15 2004-06-24 グラクソ　グループ　リミテッド 治療用化合物
WO2002048148A2 (en) * 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ES2227451T3 (es) * 2001-03-08 2005-04-01 Smithkline Beecham Corporation Derivados de pirazolopiridina.
WO2002078700A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
US20050107400A1 (en) * 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ES2242028T3 (es) * 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
IL158667A0 (en) * 2001-06-21 2004-05-12 Smithkline Beecham Corp Imidazo [1,2-a] pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
HUP0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP1423389B1 (de) * 2001-09-07 2007-06-06 SmithKline Beecham Corporation Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
DE60211539T2 (de) * 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
ATE373000T1 (de) * 2001-12-11 2007-09-15 Smithkline Beecham Corp Pyrazolopyridin-derivate als antiherpesmittel
EP1492506B2 (de) 2002-04-05 2016-06-29 Euro-Celtique S.A. Matrix für die modifizierte freigabe von aktiven substanzen
WO2003088814A2 (en) 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PT2270048E (pt) * 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US7282519B2 (en) * 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
WO2005077344A2 (en) 2003-08-29 2005-08-25 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
KR100647583B1 (ko) * 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
WO2005055810A2 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
HUE037549T2 (hu) 2004-04-07 2018-09-28 Rinat Neuroscience Corp Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
AU2005304770A1 (en) * 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
JP2008520578A (ja) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
AU2006206249A1 (en) * 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1861093A2 (de) * 2005-03-09 2007-12-05 Nitromed, Inc. Organische stickoxide verbessernde salze von angiotensin-ii-antagonisten , zusammensetzungen und verwendungsverfahren
EP1889198B1 (de) 2005-04-28 2014-11-26 Proteus Digital Health, Inc. Pharma-informatiksystem
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
EP1942909A4 (de) * 2005-10-04 2010-01-06 Nitromed Inc Verfahren zur behandlung von atemwegserkrankungen
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1968584A2 (de) * 2005-12-20 2008-09-17 Nitromed, Inc. Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
EP1971340A2 (de) * 2005-12-22 2008-09-24 Nitromed, Inc. Stickoxid-verstärkende pyruvat-verbindungen, zusammensetzungen und anwendungsverfahren
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
EP2030025A2 (de) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Mit arteriovaskulären ereignissen assoziierte marker und verfahren zu ihrer verwendung
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2008131224A2 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
EP2427178B1 (de) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermale freisetzungszusammensetzung mit wirkstoff-calciumphosphat-partikelkomplexen und anwendungsverfahren
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110190807A1 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
LT3333188T (lt) 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN103370058A (zh) 2010-12-22 2013-10-23 普渡制药公司 包覆的抗篡改控制释放剂型
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
LT3495392T (lt) 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
TWI643845B (zh) 2012-05-11 2018-12-11 重植治療公司 隱花色素調節劑之含咔唑磺醯胺類
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
GB201321731D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
WO2019177690A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
CN112752761B (zh) 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
MA53652A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg de haute pureté et leurs utilisations
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
KR20240049275A (ko) 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064260A (en) * 1976-07-29 1977-12-20 E. I. Du Pont De Nemours And Company Anti-inflammatory diarylimidazothiazoles and their corresponding S-oxides
US4263311A (en) * 1976-09-27 1981-04-21 Smithkline Corporation 5,6-Phenyl-2,3-dihydroimidazo [2,1-b] thiazoles
ZA775268B (en) * 1976-09-27 1978-07-26 Smithkline Corp Pharmacologically active compounds
LU77703A1 (de) * 1977-07-07 1979-03-26 Ciba Geigy Ag Verfahren zur herstellung von bicyclischen thia-diaza-verbindungen
US4175127A (en) * 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
US4186205A (en) * 1979-01-08 1980-01-29 Smithkline Corporation 2,3-Di(4-substituted phenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
ZW24186A1 (en) * 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
JPH04506215A (ja) * 1989-06-13 1992-10-29 スミスクライン・ビーチャム・コーポレイション モノカイン活性干渉
KR930700104A (ko) * 1990-06-12 1993-03-13 원본미기재 5-리프옥시게나제 및 사이클로옥시게나제 경로 개재된 질병의 억제
WO1992010498A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
WO1992010190A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids

Also Published As

Publication number Publication date
ATE208397T1 (de) 2001-11-15
EP0802917A1 (de) 1997-10-29
DE69616749T2 (de) 2002-08-01
JPH11501902A (ja) 1999-02-16
AU4381496A (en) 1996-07-31
US5552422A (en) 1996-09-03
ES2165969T3 (es) 2002-04-01
AU697650B2 (en) 1998-10-15
EP0802917B1 (de) 2001-11-07
CA2209895A1 (en) 1996-07-18
WO1996021667A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
PT828724E (pt) Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2
ATE232856T1 (de) Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
YU54896A (sh) (methilsulfonil)fenil-2-(5h)-furanoni kao cox-2 inhibitori
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
RU94044454A (ru) Ингибитор аутоимунных заболеваний
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
CA2180624A1 (en) Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
EA200001028A1 (ru) Производные 2"-деоксигигромицина

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee